EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma

David Tougeron, Fernando Rivera, Tania Fleitas Kanonnikoff, Karine Le Malicot, Meriem Guarssifi, Nadim Fares, Emilie Soularue, Melanie Dos Santos, Mathilde Wagner, Julien Taieb, Thomas Aparicio, Pierre Laurent-Puig und 4 weitere

Digestive and Liver Disease · 2026-06 · 58 (6) · 765-772

DOI: 10.1016/j.dld.2026.04.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive and Liver Disease, 2026-06. Verfasst von David Tougeron und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology and Gastroenterology, Poitiers University Hospital and Poitiers University, Poitiers, France. Electronic address: david.toug…. Hauptthemen laut MEDLINE: Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms, Pyrrolidines. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceuticals USA Inc, Ligue Contre le Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsPyrrolidinesQuinazolinesStomach NeoplasmsThymineTrifluridineHumansDrug CombinationsEsophagogastric JunctionResearch DesignUracilRandomized Controlled Trials as TopicClinical Trials, Phase III as TopicMulticenter Studies as TopicBenzofurans

Stichwörter der Autor:innen

FruquintinibGastric adenocarcinomaOesophageal adenocarcinomaPhase IIITrifluridine/tipiracil

Substanzen

Drug CombinationsHMPL-013PyrrolidinesQuinazolinesThymineTrifluridinetrifluridine tipiracil drug combinationUracilBenzofurans

Autor:innen und Institutionen

  • Department of Hepatology and Gastroenterology, Poitiers University Hospital and Poitiers University, Poitiers, France. Electronic address: david.tougeron@chu-poitiers.fr.
  • Departamento de Oncología Médica, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
  • Medical Oncology Department. Hospital Clinico Universitario de Valencia, INCLIVA Biomedical Research Institute, Valencia, Spain.
  • Fédération Francophone de Cancérologie Digestive (FFCD), EPICAD INSERM LNC-UMR 1231, Université Bourgogne Europe, Dijon, France.
  • Department of digestive oncology, Toulouse University hospital and Toulouse University, Toulouse, France.
  • Department of Medical Oncology, Institut Mutualiste Montsouris, Paris, France.

Förderung

  • Takeda Pharmaceuticals USA Inc
  • Ligue Contre le Cancer

Zitieren

APA

Tougeron, D., Rivera, F., Kanonnikoff, T. F., Le Malicot, K., Guarssifi, M., Fares, N., Soularue, E., Dos Santos, M., Wagner, M., Taieb, J., Aparicio, T., Laurent-Puig, P., Hacker, U. T., Fernández Montes, A., Al-Batran, S. E., & Lordick, F. (2026). FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma. Digestive and Liver Disease, 58(6), 765-772. https://doi.org/10.1016/j.dld.2026.04.004

Vancouver

Tougeron D, Rivera F, Kanonnikoff TF, Le Malicot K, Guarssifi M, Fares N, et al. FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma. Digestive and Liver Disease. 2026;58(6):765-772. doi:10.1016/j.dld.2026.04.004

BibTeX
@article{Tougeron2026,
  author = {Tougeron, David and Rivera, Fernando and Kanonnikoff, Tania Fleitas and Le Malicot, Karine and Guarssifi, Meriem and Fares, Nadim and Soularue, Emilie and Dos Santos, Melanie and Wagner, Mathilde and Taieb, Julien and Aparicio, Thomas and Laurent-Puig, Pierre and Hacker, Ulrich T and Fernández Montes, Ana and Al-Batran, Salah-Eddin and Lordick, Florian},
  title = {FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma},
  journal = {Digestive and Liver Disease},
  year = {2026},
  volume = {58},
  number = {6},
  pages = {765--772},
  doi = {10.1016/j.dld.2026.04.004}
}
Kostenlos starten →